Advances in Pharmacology and Pharmacy Vol. 10(2), pp. 138 - 144
DOI: 10.13189/app.2022.100208
Reprint (PDF) (262Kb)

Mohamed Abdellatif *
Pharmacy Department, Chilliwack General Hospital, Chilliwack, V2P1P7, British Columbia, Canada

ABSTRACT

Venous thromboembolism (VTE) is reportedly the second common cause of death among cancer patients. Management of VTE with low molecular weight heparins (LMWH) and Vitamin K antagonists (VKA) is associated with significant clinical challenges that led to the emergence of direct oral anticoagulants (DOAC) as an alternative for the management of cancer-associated thrombosis (CAT). The objective of this review is to provide an updated review of the completed and upcoming randomized controlled clinical trials (RCT) comparing the safety and efficacy of DOAC versus LMWH in the management of CAT in adults. A comprehensive literature survey was conducted till 7th January 2021 to review the completed randomized controlled clinical trials (RCT) comparing the safety and efficacy of DOAC versus LMWH in the management of CAT in adults. In order to search for upcoming trials, the Cochrane library and clinicaltrials.org databases were surveyed until the same period. The author found four completed RCT of DOAC in the management of CAT. Apart from these, there were another four RCT that are either ongoing or are yet to publish data. DOAC were reported to be noninferior to LMWH in the treatment of cancer-associated thrombosis in cancer patients with low bleeding risk and without gastrointestinal or gastrourinary cancers. Among patients with gastrointestinal or gastrourinary cancers and VTE, LMWH are preferred.

KEYWORDS
Venous Thromboembolism, Cancer, DOAC

Cite This Paper in IEEE or APA Citation Styles
(a). IEEE Format:
[1] Mohamed Abdellatif , "Direct Oral Anticoagulants in the Management of Cancer-Associated Venous Thromboembolism: A Comprehensive Review," Advances in Pharmacology and Pharmacy, Vol. 10, No. 2, pp. 138 - 144, 2022. DOI: 10.13189/app.2022.100208.

(b). APA Format:
Mohamed Abdellatif (2022). Direct Oral Anticoagulants in the Management of Cancer-Associated Venous Thromboembolism: A Comprehensive Review. Advances in Pharmacology and Pharmacy, 10(2), 138 - 144. DOI: 10.13189/app.2022.100208.